Skip to content

Fenebrutinib Maintains Low Disease Activity in Relapsing Multiple Sclerosis: Clinical, Safety and Biomarker Results From the FENopta Open-Label Extension

This analysis assessed the efficacy, safety and exploratory biomarkers, such as immunoglobulins and B cells, after fenebrutinib treatment in people with RMS enrolled int he FENopta open-label extension through Week 48.

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

Send Via Email

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.

Leave Site Stay on Medically